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Abstract  
    Two-dimensional (2D) graphene, sp
2
-hybridized carbon, and its two major derivatives, 
graphene oxide (GO) and reduced graphene oxide (rGO) have played an important role in 
immunoassays (IAs) and immunosensing (IMS) platforms for the detection of carcinoembryonic 
antigen (CEA), an implicated tumor biomarker found in several types of cancer. The graphene 
family with high surface area is functionalized to form stable nanocomposites with gold 
nanoparticles (AuNPs) and electron mediators. The capture anti-CEA antibody (Ab) with high 
density can be anchored on AuNPs of such composites to provide remarkable detection 
sensitivity, significantly below the level found in normal subjects and cancer patients. 
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Electrochemical and fluorescence/chemiluminescence-quenching properties of graphene-based 
nanocomposites are exploited in various detection schemes. Future endeavors are envisioned for 
the development of an array platform with high-throughput for CEA together with other tumor 
biomarkers and C-reactive protein, a universal biomarker for infection and inflammation. The 
ongoing efforts dedicated to the replacement of a lab-based detector by a cellphone with smart 
applications will further enable cost-effective and frequent monitoring of CEA in order to 
establish its clinical relevance and provide tools for real-time monitoring of patients during 
chemotherapy. 
 
Keywords 
graphene, graphene oxide, reduced graphene oxide, carcinoembryonic antigen, immunoassay, 
immunosensing platform, electrochemical sensing, chemiluminescence, fluorescence quenching. 
 
 
Introduction 
    IAs using polyclonal or monoclonal antibody (Ab) serve as a workhorse in analytical, clinical, 
forensic, and environmental monitoring for the detection of biomarkers, protein/enzyme, DNA, 
tumor cells, viruses, small molecules, etc. with remarkable detection sensitivity and selectivity. 
Conventional IAs are based on the binding of capture Ab (cAb) to a typical polystyrene-based 
microtiter plate (MTP) to capture a target antigen to form an immunocomplex (IMC). Both 
simple adsorption and covalent binding strategies are employed for the immobilization of cAb on 
the pristine or modified MTP surface. Among various detection schemes, this IMC is often 
allowed to form a tertiary complex with a detection antibody (dAb), a format known as a 
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sandwich assay. The dAb is pre-conjugated with a fluorescence dye, an electroactive species, 
gold nanoparticles (AuNPs), silver nanoparticles (AgNPs), quantum dots, etc. to enable the 
binding event’s quantitation. The dAb can also be labeled with an enzyme, known as enzyme-
linked immunosorbent assays (ELISA), where its reaction with a corresponding substrate can be 
monitored and quantified by different detection procedures. The confinement of cAb on a 
sensing chip or an electroactive surface form the basis for the development of electrochemical 
(EC) or optical IMS biosensing. Accordingly, bioelectrocatalysis of H2O2 and the luminol/H2O2 
chemiluminescence reaction catalyzed by labeled horseradish peroxidase (HRP) are often used 
due to their simplicity, high detection sensitivity and reliability (Huang and Ren, 2011).   
2D graphene, sp
2
-hybridized carbon, has emerged recently as a nanoscale material with high 
surface area and other important properties including excellent electrical conductivity and a 
small band gap (Geim, 2009). Electronic properties of graphene have been discussed widely in 
the literature (Peres et al, 2006) and will not be addressed here.  In graphene, the sp
2
-orbitals 
form three strong covalent bonds to the nearest neighbors, resulting in its extraordinary 
mechanical strength. The remaining -electron per atom is delocalized over the graphene planar 
surface, which is in turn responsible for electrical conductivity. Such electrons can travel large 
distances without being scattered, rendering it a promising nanomaterial for fast electronic 
components (Neto et al, 2004).  
Biocompatibility of graphene-based materials has also received considerable attention due to 
their potential applications in biomedicine, biosensing and tissue engineering (Pinto et al, 2013). 
Although detailed and longer-term studies for toxicities of graphene and its related materials are 
needed for in vivo biomedical graphene applications, graphene has been widely used in 
biosensing and analytical sciences. This material can be used to modify the surface of an MTP or 
 4 
 
a sensing chip/electrode to accommodate very high biomolecule loadings to improve detection 
sensitivity and other bioanalytical parameters. There are considerable advances in the synthesis 
and characterization of graphene, GO and reduced graphene oxide (rGO), hereafter defined as 
the graphene family. Of notice is the fabrication of the high-quality sheets of few-layer graphene 
via chemical vapor deposition (CVD) on thin nickel films (Rafiee et al, 2012). Graphene-based 
electrodes exhibit superior electrocatalysis over carbon nanotubes (CNTs) (Alwarappan et al, 
2009) and significantly lower charge-transfer resistance compared to graphite and glassy carbon 
(GC) materials (Zhou et al, 2009). The graphene family also forms nanocomposites with 
polymers, conducting polymers, electron mediators, biomolecules, surfactants, and other 
nanomaterials including quantum dots and metal nanoparticles (Hu et al, 2014, Premkumar and 
Geckeler, 2012). Negatively charged GO with ionic groups and aromatic domains bind dyes, 
electroactive molecules and charged proteins via electrostatic as well as - stacking 
interactions. Such nanocomposites can be patterned on a substrate and exploited in IAs and 
diversified biosensing platforms with excellent analytical performance.  
This review aims to unravel the role, current pending technical issues and future feasibility of 
this fascinating 2D nanomaterial in various IA formats and detection schemes for the detection of 
CEA, an important tumor marker for colorectal and other types of cancer.  
 
General features of graphene 
Among several literature procedures, CVD on metallic surfaces would lead to the synthesis of 
single, few, or multilayer graphene. Graphene nanoplatelets (GNPs) are also commercially 
available in a granular form with an average thickness of 6-10 nm and various sizes up to 50 
microns. The MTP is made of hydrophobic polystyrene, a long carbon chain with pendant 
benzene rings on every alternate carbon. Hence, a non-treated MTP surface should interact 
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strongly with the graphene family via hydrophobic interaction to form a stable layer with an 
enhanced surface area. To date, the graphene family has been widely used for surface 
modification by drop-casting of a graphene material dispersed in organic solvents on the sensing 
interface. For multi-analyte detection with high-throughput, ELISA plates with 96 wells or 
higher density are commercially available and readily usable in various optical detection 
schemes. Electrodes can be embedded in the well bottom of such plates for electrochemical 
analysis in an array. The benzene ring of the polystyrene-based MTP lends itself to chemical 
modification/ radiation to form amine and carboxyl groups. Other reactive groups, N-
hydroxysuccinimide, maleimide and hydrazide groups, can also be grafted onto a polystyrene 
surface via a photo-linkable spacer arm. The resulting slightly ionic, hydrophobic surfaces with 
high binding capacities exhibit hydrophobic as well as ionic interactions with GO or rGO to form 
a stable interface layer for the subsequent modification, bioconjugation, and immunosensing. A 
regular array of GO sheets can also be patterned at a localized site on a microscope slide or a 
similar substrate (Figure 1). The fabrication procedure involves both negatively charged GO with 
COOH groups and positively charged GO with amine NH2 groups, as the latter can be prepared 
by surface functionalization with ethylenediamine via the well-known EDC reaction. COOH-GO 
adheres on the aminated-glass slide with an opposite charge by electrostatic attraction. An array 
of multilayer thin films is fabricated by alternate layer by layer application of the two GO 
suspensions (Jung et al, 2013).   
 
**Insert Figure 1 here** 
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As a prerequisite for surface modification and bioconjugation, GNPs must be dispersed as a 
stable suspension in order to exploit their optimal properties including high surface areas ranging 
from 300-750 m
2
 g
-1
. However, due to significant π–π interactions, GNPs cannot be stabilized as 
a concentrated mixture regardless of the preparation method. The dispersion of GNPs will cease 
once the suspension attains a threshold electrical resistance regardless of the time and power 
used for sonication. In general, smaller GNPs are dispersed more effectively than their bigger 
counterparts, and low viscous matrices provide a better dispersion with ultrasonication. Among 
various attempted solvents and surfactants  (Table 1A), the most popular for this purpose are N-
methylpyrrolidone (NMP) and an expensive ionic liquid, which only result in 2.1 mg mL
-1
 
(Alzari et al, 2011) and 5.33 mg mL
-1
 (Nuvoli et al, 2011), respectively, of dispersed GNPs. 
Other novel graphene solvents offer better dispersion compared to NMP (Table 1B).   
Of interest is the use of 3-aminopropyltriethoxysilane (APTES), a simple silane, to disperse 
hydrophobic graphene to form a suspension (Vashist et al, 2014). The graphene modified MTP 
provides a significant increase in the surface area to accommodate high biomolecule loadings. 
The APTES-NH2 group is then readily crosslinked with the free NH2 of the capture antibody by 
glutaraldehyde activation. Alternatively, the APTES-NH2 wrapped on MTP and GNPs can be 
crosslinked with the cAb-COOH groups via EDC activation. After modification, the solvent 
must be removed from the resulting interface as required for the subsequent bioconjugation 
steps. Therefore, NMP with a high boiling point of 205 °C compared to 56 °C for acetone is 
difficult to evaporate from the interface. Similarly, noncovalent modification of graphene with a 
small organic molecule might exhibit inherent electrochemistry or optical property, non-specific 
binding and/or interference with the subsequent bioconjugation step. 
 7 
 
GO can be readily prepared by chemical exfoliation of graphite in fuming nitric acid (Brodie, 
1859), whereas the preparation of highly oxidized GO requires a concentrated sulfuric acid and 
fuming nitric acid mixture (Staudenmaier, 1898) or KMnO4 and NaNO3 in concentrated H2SO4 
(Hummers Jr and Offeman, 1958). The C–O bond in GO disrupts the sp2 conjugation of the 
hexagonal graphene lattice, rendering GO an insulator. A GO suspension is more stable in water 
compared to pristine graphene due to the presence of oxygen-containing groups. GO contains a 
large amount of oxygen functional groups including carboxyl groups, which form amide bonds 
with amino-terminated biomolecules. GO binds dyes, charged proteins, hydrophobic molecules 
via combined electrostatic and - stacking interactions. This feature can be exploited for 
facilitated bioconjugation and novel detection schemes as GO retains near-infrared, visible and 
ultraviolet fluorescence properties (Dreyer et al, 2010). The chemistry of GO has been widely 
discussed in the literature (Dreyer et al, 2010) and will not be repeated here. In brief, GO is 
nonconductive electrically and very defective, but can be treated with a reducing agent, e.g., 
hydrazine or EC reduction (Chng and Pumera, 2011), known as rGO with enhanced conductivity 
and electrical properties. Both GO and rGO are more soluble in deionized water (6.6 and 4.74 
mg L
-1
, respectively), and most soluble in N-methyl-2-pyrrolidone (NMP), 8.7 and 9.4 mg L
-1
, 
respectively. Similar solubility is noted for rGO in O-dichlorobenzene (8.91 mg L
-1
) and   1-
chloronaphthalene (8.1 mg L
-1
), however, GO is less soluble in these two solvents (1.91 and 1.8 
mg L
-1
). The dispersion behavior of GO and rGO in 18 common solvents including deionized 
water has been investigated by Konios et al. (2014).    
In general, both graphene and rGO are advocated in EC detection schemes to modify 
electrode materials, whereas GO plays an important role in an optical measurement platform 
with fluorescence or chemiluminescence detection. Also of interest is a novel in-situ EC 
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synthesis approach for the formation of functionalized graphene (fG)-GO nanocomposite on a 
screen-printed electrode, SPE (Sharma et al, 2013).  This approach combines good electronic 
properties of fG and reactive groups of GO for bioconjugation with biomolecules. SPE has been 
advocated and commercialized as disposable electrodes for a single use.  
 
Fundamental aspects of bioconjugation  
    For IAs using a polystyrene-based MTP, graphene or its derivatives is simply coated into the 
containment vessel (well) to drastically increase the binding surface for the cAb.  After binding 
to graphene, the cAb conformation is altered, depending on the surface chemical properties. In 
many cases, the cAb unfolds to expose hydrophobic regions that interact with the hydrophobic 
surface of graphene by passive adsorption.  Modified graphene with a small number of ionic 
carboxyl groups results in a slightly ionic, hydrophobic surface. This feature is very important as 
biomolecules adsorb passively to surfaces through hydrophobic and ionic interactions. During 
the course of IAs, as several washing steps are required for the removal of unbound materials, a 
covalent binding provides a more stable biomolecule layer on graphene. In this case, GO or rGO 
with a large amount of oxygen functional groups including carboxyl groups must be used. The 
formation of amide bonds between amino-terminated biomolecules and carboxyl groups of 
modified graphene is a well-known strategy for bioconjugation. The most versatile crosslinker in 
aqueous preparation, 1-ethyl-3-(-3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), 
reacts with carboxylic acid groups to form O-acylisourea, a carboxylic ester with an activated 
leaving group as the key intermediate (Vashist, 2012). The O-acylisourea intermediate then 
reacts with amines to give the desired amide. However, as O-acylisourea is not very stable, the 
preferred crosslinking chemistry is the use of EDC with N-hydroxysuccinimide (NHS) or N-
hydroxysulfosuccinimide (Sulfo-NHS) (https://www.thermofisher.com/us/en/home/life-
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science/protein-biology/protein-biology-learning-center/protein-biology-resource-library/pierce-
protein-methods/carbodiimide-crosslinker-chemistry.html). Alternatively, carboxyl- or amino-
containing molecules, e.g., perylene tetracarboxylic acid, poly(xanthurenic acid)  and 1-
aminopyrene, form stable complexes with graphene to enable covalent attachment. GNPs can 
also be modified to possess positively charged amine groups, which ionically couple to small 
negatively charged biomolecules. This surface is specifically designed to be used with 
bifunctional crosslinkers such as glutaraldehyde and carbodiimide to covalently couple to 
primary amines, thiols or carboxyls on Ab. 
Considering Ab heavy chains located in a flexible region are joined by a disulfide bond, and 
like thiols, disulfides bind strongly to gold surfaces to form self-assembled monolayers 
(Grönbeck et al, 2000). Thus, graphene materials decorated with gold nanoparticles (AuNPs) can 
be conjugated with Ab by exploiting “well-known Au−S” interactions. Although the true nature 
of Au-S bonds is still unclear, the S-S bond is plausibly cleaved by the Au atoms on the Au 
surface upon its contact to thiolates, which in turn self-assemble on Au. The surface chemistry of 
Au colloids related to its negative surface charge and their interactions with functional amino 
acids has been described by Zhong et al. (2004). AuNPs with high surface-to-volume ratio and 
surface energy interact strongly with protein/enzyme to form a stable biolayer (Colvin et al, 
1992).    
 
CEA as a tumor biomarker 
CEA is an important tumor biomarker for colorectal and some other carcinomas and its assay is 
widely accepted in the oncology practice as a useful and cost-effective tool for monitoring colon 
cancer after surgery. In the past, CEA was considered as an oncofetal antigen, expressed during 
the embryonic development and re-expressed only in cancer patients. Indeed, CEA is also 
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expressed in normal adults but it is produced in the colon and then disappears in feces. This cell 
surface glycoprotein plays a role in cell adhesion and in intracellular signaling. In colon cancer, 
the tumor cells have lost their polarity and CEA is distributed around the cell surface and 
eventually gets into the blood (Taylor and Black, 1985). CEA is a complex, highly glycosylated 
macromolecule (50 % carbohydrates) with a molecular weight of 200 kDa (Hammarstrom et al, 
1975), compared to 160 kDa for well-known glucose oxidase. Indeed, CEA in normal colon 
tissues has a broad band averaging at 200 kDa and a sharp band at 130 kDa. However, in cancer 
cells, only a single band at 170 kDa or lower has been observed, which is partly due to the 
modification of the glycosylation pattern of CEA by N-glycanase (Garcia et al, 1991). As a 
stable molecule, CEA is one of the most widely used tumor biomarkers and a prognostic 
indicator in clinical assays.  
CEA should be minimal in the blood of healthy adults whereas an abnormal level of CEA 
may be a sign of cancer, especially colon and rectal cancer. Serum from patients with colorectal 
carcinoma often has higher CEA level than healthy individuals, 2.5 µgL-1 (Ballesta et al, 1995). 
CEA may also be present in patients with pancreas, liver, breast, ovary, or lung cancer (Figure 
2). Therefore, the CEA level measured before and after surgery indicates the surgical success and 
the prognosis of patient’s recovery. CEA levels may also be measured during chemotherapy to 
evaluate the treatment progress and outcome. 
 
**Insert Figure 2 here** 
 
Immunosensing procedures for CEA 
Among various commercial anti-CEA Ab obtained from mouse and rabbit, some Ab has 
specific reactivity with human, whereas others exhibit some cross-reactivity with monkey or 
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mouse/rat. Although graphene can be functionalized to form the covalent binding with the cAb, 
in most cases, graphene forms a nanocomposite with AuNPs, polymers, etc. to facilitate 
bioconjugation of the cAb, which forms an IMC with a target protein. Several procedures have 
also been attempted for the preparation of Au colloids including the popular route based on the 
reduction of hydrogen tetrachloroaurate(III) trihydrate by sodium citrate. In addition, a small 
molecule is added during the course of synthesis to control the size and distribution of AuNPs 
(Liu et al, 2003). Electrochemical deposition of AuNPs on the surface of an electrode, e.g. gold 
(Li et al., 2005) or GC (Majid et al., 2006), is another convenient and rapid way to increase the 
active surface area. The size and density of AuNPs on such electrodes are mainly controlled by 
the deposition time and the concentration of the Au salt solution besides the applied potential.   
HRP, often used to label the dAb, binds to the Fc region of the capture antibody.  This 
enzyme is a 44 kDa glycoprotein with 6 lysine residues which are easily conjugated to a labeled 
molecule. Through the binding, HRP along with the heme iron Fe (III) quickly catalyzes the 
reduction of H2O2 in the presence of an electron mediator, e.g., tetramethylbenzidine (TMB) to 
produce a blue color solution (the resulting diimine), which can be read at 650 nm. The TMB-
peroxidase pair is used extensively in ELISA with a colorimetric reader (Figure 3). Chloro-1-
naphthol (4CN) (Hawkes et al., (1982) is another common substrate for this enzyme besides 
Prussian blue, Nile blue, toluidine blue, thionine, methylene blue, methylene green, ferrocene, 
hydroquinone, etc. For higher detection sensitivity, several fluorophores are also available for 
HRP: cyanine and fluorescein, nanocrystals of semiconductor material, and naturally fluorescent 
proteins such as phycoerythrin and allophycocyanin. The dAb can also be labeled with a dye, an 
electroactive species, QDs, NPs. However, IA with Au-labeled secondary antibodies has 
relatively low sensitivity and the signal is not permanent. Silver enhancement enhances the 
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detection sensitivity, which is equivalent to colorimetric alkaline phosphatase (AP) detection. AP 
is another labeled enzyme in immunoassays, but it is more expensive than HRP.  
 
**Insert Figure 3 here** 
 
In EC IMS, graphene can be used to modify other carbon material electrodes, ranging from 
graphite, carbon paste, GC, carbon nanotubes (CNTs) and even boron doped diamond. The 
electron mediator can be anchored together with the HRP-conjugated dAb on NPs to simplify the 
detection scheme. Of interest is nanoporous silver (NPS) with high specific surface area, 
electrical conductivity and adsorption capacity for a high loading of a suitable mediator (Liu et 
al, 2010). Thionine together with HRP significantly simplified improves the detection sensitivity 
of CEA (Figure 4). A similar approach using thionine and functionalized GO has been reported 
for the detection of phosphorylated p53 (S392), a potential biomarker in clinical diagnosis (Du et 
al, 2011). Alternatively, after binding to the cAb-CEA complex, the labeled HRP will be close 
contact with the electrode surface to catalyze H2O2 reduction and this approach has been 
frequently used in EC immunoassays. Without the enzyme, the graphene electrode does not 
exhibit high electrocatalysis for H2O2 reduction.   
Considering label-free assays, electroactive molecules such as thionine and methylene blue 
(MB) form stable complexes with graphene/graphene derivatives via - stacking and ionic 
interactions. MB displays a quasi-reversible process with two-electron transfer with one proton 
(Tani et al., 2001) while its reduced form is colorless. MB shows peak absorption at 609 nm and 
668 nm. Prussian blue is ferric ferrocyanide (   
    [Fe
II
(CN)6]3) with alternating iron(II) and 
iron(III) located on a face of the cubic structure. Prussian blue is reduced to become Prussian 
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white (   
   [Fe
II
(CN)6]3) with the loss of 4 electrons (Karyakin, 2001). If both the amines of 
thionine are dimethylated, the product tetramethylthionine is known as famous MB. Detailed 
electrochemistry of such dyes are well documented in the literature and deoxyribonucleic acid 
(DNA) electrochemistry with tethered MB has received considerable interest (Pheeney and 
Barton, 2012).  The electron transfer from the excited MB to graphene is more efficient than to 
GO, owing to the different electrostatic attraction between the dye and graphene. In this context, 
MB, AuNPs and anti-CEA “layer-by-layer” self-assemble on a graphene-Nafion modified 
electrode (Figure 5). This is a label-free and simplified approach for the detection of CEA with 
high detection sensitivity (Li et al, 2011).    
 
**Insert Figure 4 here** 
**Insert Figure 5 here** 
 
Investigation of fluorescence quenching of dyes by graphite oxide and graphene including a 
suggested mechanism can be found elsewhere (Liu et al, 2011). GO also quenches tryptophan or 
tyrosine containing peptides and proteins and electrostatic interaction plays an important role 
during quenching. Static quenching is the main mechanism, combined with Förster resonance 
energy transfer or dynamic quenching (Li et al, 2012). This is the rationale behind the use of GO 
together with a fluorescence dye in various IA formats.  The binding of CEA to such a 
biofunctionalized surface exerts a strong steric effect, which reduces the electron transfer of the 
mediators. Of notice is the quenching behavior, known as fluorescence resonance energy transfer 
(FRET) (Loh et al, 2010) exhibited by GO.  Neighboring fluorescent species to the graphitic 
carbon of GO are quenched by long-range “energy and electron” transfer (Swathi and Sebastian, 
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2008), which can be exploited for homogeneous assays of CEA and other biomolecules of 
interest. Chemiluminescence resonance energy transfer (CRET), however, occurs via non-
radiative dipole-dipole energy transfer from a donor to an acceptor without an external excitation 
source.  In the CRET platform with luminol, graphene is a better energy acceptor than GO, (Lee 
et al., 2012) as shown in Figure 6. Oxygenated functionalities are introduced in the graphite 
structure, which expand the layer separation and disrupt the sp
2
 configuration. As a consequence, 
GO possesses a recombination of localized electron–hole pairs in a small sp2 carbon domain 
within a sp
3
 matrix. With luminol as the donor, the energy transfer efficiency is 72% for 
graphene and 36% for GO. Such a result is attributed to large Stokes shifts and long-range 
energy transfer efficiency of graphene (Lee et al, 2012) compared to GO. Molecules and 
nanomaterials with small Stokes shifts, i.e., low spectral separation of the acceptor emission 
from the donor emission should have a low energy transfer efficiency (Morales-Narvaez and 
Merkoci, 2012).  Nevertheless, GO with a high planar surface, ∼ 2620 m2 g-1 (Stankovich et al, 
2006), serves as an excellent platform for biomolecule loading and its potential use as an energy 
acceptor requires further investigation. 
**Insert Figure 6 here** 
 
Trends in technology for the detection of CEA 
    Albeit, color, fluorescence and EC measurements are often used to detect the binding event, of 
significance is a graphene-based CRET  platform with remarkable detection sensitivity for 
homogeneous IA for C-reactive protein (CRP) (Lee et al, 2012). In this detection scheme, the 
anti-CRP Ab is conjugated to graphene nanosheets (with sulfonic acid groups) to capture and 
detect CRP at 1.6 ng mL
-1
 using the luminol/H2O2 chemiluminescence reaction catalyzed by 
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labeled HRP. CRET occurs via nonradiative dipole-dipole transfer of energy from luminol to 
graphene as mentioned previously.  This efficient assay platform requires no removal of unbound 
antibody or phase separation and can be easily extended for other biomolecules of interest 
including CEA. 
Electrochemiluminescence (ECL) is another new trend in particle-based IAs.  An ECL label is 
tagged to NP bioconjugates, which are immobilized on the electrode surface. The most popular 
ECL label, tris(2,20-bipyridyl)ruthenium(II), ([Ru(bpy)3]
2+
), emits light when it reacts with ions, 
enzymes, tripropylamine (TPrA), etc. The reductant is oxidized at the electrode surface, which 
reacts with [Ru(bpy)3]
2+
 to yield [Ru(bpy)3]
3+
, which is measured by a photomultiplier, a charge-
coupled device, etc. Magnetic NPs offer an ease of functionalization and enrichment of 
biomarkers from the complex mixtures, such as blood/serum. Together with ECL, this 
technology will find its widespread application to monitor the trace level of CEA or other 
pertinent biomarkers in whole blood.  
A label-free technique based on surface plasmon resonance (SPR) also deserves a brief 
mention considering some recent developments in SPR biosensing with graphene modified 
sensing gold chips. A graphene sheet can be used to coat an Au SPR chip to increase the 
adsorption of biomolecules (Wu et al, 2010). GO can self-assemble on an SPR Au surface 
modified by 1-octadecanethiol to provide remarkable detection sensitivity for bovine serum 
albumin, down to 100 of pg mL
-1
 compared to 10 μg mL-1 for conventional SPR, i.e., about 100-
fold more sensitive (Chiu et al, 2014). Indeed, protein A was conjugated on a gold surface of an 
SPR sensing chip and then coupled with anti-CEA Ab for detecting purified CEA with a limit of 
detection (LOD) of  0.5 ng mL
-1
 (Tang et al, 2006), well below the normal level in blood.  With 
the graphene modified Au chip, the detection sensitivity should be significantly lower as 
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anticipated from the work of (Chiu et al, 2014). However, it is a formidable task to fabricate a 
multi-channel SPR and the cost of this instrument including disposable Au sensing chips could 
be another issue for its acceptance in clinical and hospital settings.  
Direct electron transfer (DET) is another important feature in the construction of an efficient 
and “reagentless” electrochemical platform. Direct electron transfer (DET) to HRP is well established 
in contrast to glucose oxidase (GOx) where DET is highly unlikely (Liang et al. 2015).  HRP is a very 
small enzyme (44 kDa) with the active heme group well exposed to the solution. It is also a very 
non-specific enzyme. In contrast, GOx is a 160 kDa protein with high substrate specificity. 
Although frequent claims of DET of GOx on graphene surface have been made (Shan et al, 
2009), the evidence is not at all persuasive or even unlikely if the experiment is conducted in the 
absence of oxygen, a natural mediator of GOx (Liang et al, 2015). In brief, DET between HRP 
and an electrode is difficult because the active sites of HRP are embedded inside a thick protein 
shell. Therefore, a mediator is needed to shuttle electron from the active sites of the enzyme to 
the electrode surface.  The development of mediator-free HRP enzyme based biosensor for H2O2 
has emerged as exemplified by the DET of HRP on an AuNP modified carbon paste electrode 
(Liu and Ju, 2002),  HRP–AuNP -GNP–silk fibroin modified GCE (Yin et al, 2009), ZnO (8-10 
nm in diameter)-immobilized HRP (Xia et al, 2008), flower-like ZnO–AuNP–Nafion 
immobilized HRP (Xiang et al, 2009) and  HRP on ZnO nanorods (Gu et al, 2009).  These 
approaches improve the performance of the HRP-sensing platform for the reduction of H2O2 
without the need for a mediator. The direct electron transfer is a big subject in 
bioelectrochemistry and beyond the scope of this review. However, this important feature has 
been investigated intensively for glucose oxidase with different detection schemes and strategies, 
ranging from sophisticated chemistry involving enzyme modification, nanowire, conducting 
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polymers, etc. to simple electrode modification (Bai et al, 2014). Such knowledge should be 
considered and adapted for the development of mediator-free HRP IAs.    
Recently, different NPs have been known to exhibit intrinsic peroxidase-like activity. After the 
discovery of Fe3O4 (Gao et al, 2007), such behavior has been identified for ferromagnetic NPs 
(Shi et al, 2011), ceria oxide NPs (Asati et al, 2009), V2O5 nanowires (André et al, 2011), 
carbon-based nanomaterials (Song et al, 2010, Song et al, 2011), etc. In contrast to fragile HRP, 
NPs are very stable and retain their activity over a long period. They are not attacked by 
proteases and have greater resistance to pH, temperature, and extreme operating conditions. 
Consequently, NPs with intrinsic peroxidase activity will be integrated with graphene towards 
the development of simplified and robust IA platforms. Albeit Ab technology continues playing 
an important role in IAs, aptamers selected by in vitro selection have received considerable 
attention as affinity probes. Robust and highly stable aptamers can be designed with high affinity 
and specificity for any target including CEA. The combination of aptamers and peroxidase-like 
activity NPs could be envisioned as one of the best combinations. It should be noted that 
electrochemiluminescence of luminol is enhanced by ZnO nanoparticles, which forms the basis 
for a novel immune assay scheme for CEA (Cheng et al, 2012). However, the system is not 
completely free from enzyme since glucose oxidase is used to label the detection antibody to 
generate H2O2 in situ. Nevertheless, this enzyme is very specific for glucose which is also more 
stable than H2O2.  
Most applications for the detection of CEA rely on laboratory-based instrumentation for color, 
fluorescence, chemiluminescence and even EC measurement. Cellphone (CP)-based 
technologies with smart applications are a new trend in bioanalytical applications.  A compact 
colorimetric and fluorometric reader (Mudanyali et al, 2012), as well as a CP-based compact EC 
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sensing platform, have been reported (Lillehoj et al, 2013). Indeed, it is feasible for colorimetric 
readout from a 96-well microtiter plate (MTP) using a CP device (Vashist et al, 2015a, Vashist et 
al, 2015b) and the measurement of a full emission spectrum of any light emitter using a CP-
based fluorimeter (Long et al, 2014, Yu et al, 2014). Together with graphene as a sensing 
interface, the CP-platform doubtlessly provides cost-effective mobile healthcare and 
personalized medicine with widespread applications for point of care testing (POCT) (Vashist et 
al, 2015c). The integration of screen printed graphene electrodes (SPGE) with an enhanced 
active area with a CP based electrical platform is appealing for POCT or doctor’s office in 
remote areas. Graphene can be used to modify carbon-based screen printed electrodes and such 
products are also commercially available.    
 
**Insert Figure 7 here** 
 
Lastly, the clinical significance of CEA deserves a brief comment here as the clinician begin 
monitoring CEA levels in the cancer patients before the treatment to establish a baseline amount. 
The test will be repeated during and after treatment to assess changes over time. CEA levels 
often return to normal between one and four months after the tumors had been successfully 
removed. However, the CEA test is not useful in screening the general population for cancer. 
CEA monitoring in cancer patients, in particular, patients with colorectal cancer, is still 
controversial, which may vary from bimonthly monitoring to no monitoring in the surveillance 
setting (for stage I-III disease) and there are no clear guidelines in the metastatic setting. CEA 
monitoring in patients with other types of cancer, such as breast, lung, stomach, pancreas, ovary, 
bladder, thyroid and liver, is still unclear or debatable. Future endeavors may benefit from 
 19 
 
evaluating CEA with other biomarkers to create a more precise index for cancer prognosis and 
recurrence. Thus, CEA might need to be measured with other tumor markers such as human 
epidermal growth factor receptor 2 (HER2, breast cancer cells), prostate-specific antigen (PSA, 
prostate cancer), cancer antigen 125 (CA 125, ovarian cancer cells), as well as CRP, a general 
biomarker for inflammation and infection. Conceptually, different capture antibodies can still be 
anchored on the same interface, however, second antibodies need to be conjugated with probes 
with different electrochemical or optical properties. As an example, carboxyl graphene sheets 
can interact strongly with toluidine blue or Prussian blue, followed by bioconjugation to serve as 
two different sensing probes (Figure 7). Indeed, this approach has been developed for the 
detection of CEA and alpha-fetoprotein as discussed in Table 2 (Chen et al, 2013). Finally, there 
is also a need to devise and validate prospective multiplexing strategies, enabling the precise 
determination of CEA in a sample together with such biomarkers. With the improved diagnosis, 
specific treatment can be offered to the patients to attain better treatment outcome.  
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Table Legends 
Table 1. Dispersion and solubility of graphene.  
Table 2. Immunosensing procedures for CEA. 
 
Figure legends 
Figure 1. Schematic representation of (a) the layer-by-layer (LbL)-assembled graphene oxide 
(GO) multilayer array and (b) the aptamer-based protein sensing mechanism of the LbL GO 
multilayer array (Jung et al, 2013). Reproduced with permission from the Nature Publishing 
Group.  
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Figure 2. Carcinoembryonic antigen (CEA), a highly glycosylated cell surface protein of 
molecular mass about 180 kDa. It is found in the tissue of a developing fetus and cancer tumors. 
Not all cancers produce CEA, however,  increased levels of CEA may be found in colorectal 
(colon), breast, liver, lung, ovary, pancreas, prostalemedullary thyroid carcinoma, and protate 
cancer. The pictures of various organs are obtained from Google.  
Figure 3. Principle of "sandwich" immunoassays. Graphene or its derivatives  can be integrated 
with AuNPs to serve as an immobilization matrix for the capture antibody (cAb). CEA from the 
assay sample forms an immunocomplex with the cAb and this binding event can be detected by a 
labeled antibody, known as the detection antibody or and the secondary antobody. The label is an 
enzyme, like horseradish peroxidase (HRP), a fluorescent tag including quantum dots (QDs), 
electroactive molecules, or metallic nanoparticles. In ELISA, the binding event is detected by the 
enzymatic reaction, e.g., hydrogen poeroxide is reduced by HRP in the presence of luminol to 
produce a chemiluminescence signal.  
Figure 4. A detection scheme for the development of an electrochemical (EC) immunosensor. 
The capture antibody (Ab1) is immobilized on AuNP-decorated 3D-reduced graphene, whereas 
thionine, the electron mediator and the HRP-conjugated detetcion antibody (Ab2)  are 
successively absorbed on nanoporous silver (NPS).  DPV (differential pulse voltammetry) is 
applied to acquire high detetcion sensitivity (Sun et al, 2013). Reproduced with permission from 
Elsevier B.V. 
Figure 5. LbL self-assembly of methylene blue (MB), AuNPs and anti-CEA on a graphene-
Nafion modified electrode: (a) Formation of the graphene-Nafion nanocomposite film, (b) 
adsorption of MB, (c) formation of the AuNP monolayer, (d) anti-CEA Ab immobilization, (e) 
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bovine serum albumin (BSA) blocking, (f) CEA capturing (Li et al, 2011). Reproduced with 
permission from the Japan Society of Analytical Chemistry. 
Figure 6. Chemiluminescence resonance energy transfer (CRET) between graphene nanosheets 
and chemiluminescent donors (Lee et al, 2012).  CRET occurs via non-radiative dipole-dipole 
transfer of energy from a chemiluminescent donor to a suitable acceptor without an external 
excitation source. Immunoassay is based on a typical luminol/H2O2 (reducing oxygen species) 
chemiluminescence reaction catalyzed by HRP labeled to the detection anti-CEA Ab. 
Reproduced with permission from the American Chemical Society. 
Figure 7. Simultaneous detection of CEA and alpha-fetoprotein (AFP) using two different 
electroactive probes (Chen et al, 2013). A: preparation of two different probes using toluidine 
blue (TB) and Prussian blue, anchored on carboxyl graphene sheets, respectively, together with 
immobilized anti-CEA (upper) and anti-AFP (lower). Bovine serum albumin (BSA) is used to 
block remaining reactive sites to prevent non-specific binding. B. Immobilization of capture 
CEA and AFP on the surface of a glassy carbon electrode (GCE), which is pre-modified with 
chitosan and gold nanoparticles. Reproduced with permission from Elsevier B.V. 
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Table 1.  
A. Solvents and non-solvents for dispersion of graphene 
Solvents Acetate, acetone, 2‐aminobutane, chloroform, dimethylformamide, 
ethanol, ethyl isopropanol, γ-butyrolactone, methyl ethyl ketone,   
N‐methylpyrrolidone, toluene, tetrahydrofuran, and other polar 
solvents.  
Non-solvents 3-Aminopropyltriethoxysilane (APTES), sodium dodecylbenzene 
sulfonate, poly(sodium styrene sulfonate), polyoxyethylene 
octylphenyl ether. 
Small aromatic 
molecules containing 
hydrophilic groups via 
π−π interaction 
1-Pyrenebuyrate, p-phenyl-SO3H, methylene green, pyrene-1-
sulfonic acid pyrene-1-sulfonic acid, sodium salt and 3,4,9,10-
perylenetetra-carboxylic diimide bisbenzenesulfonic acid. 
 
B. Solubility of graphene in the most promising solvents (Hernandez et al, 2009). 
Solvents Dispersion conc. (µg L
-1
) 
Cyclopentanone 
1,3-Dimethyl-2-imidazolidinone 
N-Methyl-2-pyrrolidone-(NMP) 
N-Ethyl-2-pyrrolidone 
N-Dodecyl-2-pyrrolididone 
Acetone 
8.5 ±1.1 
5.2 ± 1.3 
4.7 ± 1.9 
4.0 ± 0.7 
2.1 ± 1.1 
1.2 ± 0.4 
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Table 2. 
Immunosensing procedure and its performance Detection range   
(LOD) 
References and other 
remarks 
AuNP–decorated graphene composites are used to modify a 
GC electrode. HRP-anti-CEA Ab and HRP are successively 
adsorbed on the Au–GN modified GC electrode. p-
hydroquinone is used as an electron mediator. Both the anodic 
and cathodic peak current responses decrease after the 
immobilization of HRP-anti-CEA, indicating the electron 
transfer between the electrode and the solution is hampered by 
the steric hindrance effect. The successive binding of HRP 
induces increased cathodic peak current corresponding to a 
decreased anodic peak current. 
0.010 to 10 ng mL
-1 
(0.04 ng mL
-1
) 
 
(Zhu et al, 2013) 
CEA in human serum 
samples are determined 
and validated by ELISA. 
Three-dimensional macroporous AuNPs/graphene composites 
serve as the working electrode and the cAb is immobilized on 
AuNPs. Thionine, the electron mediator and HRP- conjugated 
dAb are sequentially absorbed on nanoporous silver.  HRP 
reduces H2O2, whereas thionine is oxidized and recycled to its 
reduced form on the electrode surface to impart signal 
amplification.  
0.10 to 80 ng mL
-1 
(0.04 ng mL
-1
) 
 
(Sun et al, 2013) 
Good precision, stability 
and reproducibility.  
Applicable for clinical 
serum samples and in 
agreement with ELISA. 
A cryogel consisting of graphene, AuNPs and chitosan are 
prepared on an Ag modified Au electrode. Ag acts as a redox 
mediator and the cAb is immobilized on AuNPs. The decrease 
in the Ag peak current obtained by cyclic voltammetry, 
reflecting the formation of the IMC to hinder the electron 
transfer, is proportional to the CEA concentration. The 
cryogel modified approach a 25-fold lower LOD than the non-
cryogel counterpart.  
1.0×10
-6
 to 1.0 ng 
mL
-1
 
(2.0×10
-7
 ng mL
-1
) 
 
(Samanman et al, 2015) 
The results obtained from 
serum samples are in 
agreement with enzyme 
linked fluorescent assay.  
A GC electrode is modified by a nanocomposite consisting of 
AuNPs, thionine, and rGO. The anti-CEA Ab is immobilized 
on AuNPs. The decrease in the thionione peak current reflects 
the formation of an IMC complex. This complex acts as an 
insulating layer to block the electron transfer toward the 
electrode surface.  
10-500 pg mL
-1 
(4 pg mL
-1
) 
 
(Kong et al, 2011)  
Recovery experiments are 
performed by adding 40 to 
200 pg mL
-1
 of CEA in 
human serum. The 
recovery ranges from 92.5 
to 113 %.  
Layer-by-layer (based on opposite-charged interaction) of MB 
as a redox probe, AuNPs and anti-CEA Ab are self-assembled 
on a graphene-Nafion nanocomposite film-modified electrode. 
Cyclic voltammetry confirms the oxidation and reduction 
peaks of MB. The measurement of CEA is conducted by 
differential pulse voltammetry and shows that the peak current 
decreases with the increasing concentration of CEA as 
expected from the formation of the IMC on the electrode 
surface. 
0.5 to 120 ng mL
-1
 
(0.17  ng mL
-1
) 
 
(Li et al, 2011) 
The system is evaluated on 
several clinical samples 
and the obtained results 
agree well with those of 
ELISA.  
A GCE is modified by a complex film of chitosan-ferrocene 
nano-TiO2 and AuNP-graphene. The Au-graphene nanohybrid 
is formed on the complex by self-assembly. The anti-CEA Ab 
is anchored by a strong interaction between Au-graphene and 
the NH2 groups of anti-CEA Ab. The synergistic effect 
0.01 to 80 ng mL
-1
 
(3.4 pg mL
-1
) 
 
(Han et al, 2011)  
High sensitivity and long 
life time. Human serum 
samples are tested and 
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between AuNPs and graphene nanosheets results in good 
conductive response signals. 
validated by ELISA. 
 
A GC electrode is modified by AuNPs and Prussian Blue 
followed by the immobilization of the anti-CEA Ab. The 
assay is performed using HRP-conjugated anti-CEA Ab as the 
secondary Ab attached on the AuNP-graphene surface. 
Prussian blue acts as an electron mediator. 
 
0.05-350 ng mL
-1
 
(0.01 ng mL
-1
) 
 
 
(Zhong et al, 2010)  
The results obtained from 
human serum samples are in 
agreement with the 
references values 
A GC electrode is modified by a SWCNT-graphene composite 
and electrodeposited AuNPs. A sandwich protocol is used to 
generate amplified cathodic ECL signals using Pd and Pt NPs 
decorated rGO and glucose oxidase (GOD) labeled secondary 
Ab. GOD catalyzes glucose to produce H2O2 as a by-product, 
which reacts with luminol. 
0.0001 -160  ng mL
-
1
 
(0.03 pg mL
-1
) 
 
(Cao et al, 2013) 
The recovery ranges from 
96 to 109% from the 
standard addition method 
(adding CEA in normal 
human serum samples. 
A nanocomposite prepared by the self-assembly of ionic 
liquid (IL, 1-aminopropyl-3-methylimidazolium chloride) 
functionalized rGO and AuNPs via electrostatic interaction 
results in uniform AuNPs on the IL-rGO surface with high 
density. Based on a sandwich-type protocol, CEA and alpha-
fetoprotein (AFP) are co-detected using two different tags: 
Prussian blue coated chitosan NPs and cadmium 
hexacyanoferrate NPs loaded with AuNPs. The detection is 
based on differential pulse vottammetry (DPV) using 
ferri/ferrocyanide as the probe.  
0.01 to 100 ng mL
-1 
( 0.01 ng mL
-1
 for 
CEA and 0.006 ng 
mL
-1
 for AFP) 
 
 
 
(Liu and Ma, 2014)  
The results for both CEA 
and AFP are in agreement 
with ELISA. No non-
specific adsorption and 
cross-talk are noticed.  
 
 
The capture anti-CEA Ab is covalently immobilized on an 
electrochemically reduced GO/chitosan film layered on the 
surface of a GC electrode. The AuNP/mesoporous carbon 
foam (MCF) tag is prepared by in situ growth of Nanogold 
grown on carboxylated MCF (mesoporous carbon foam) 
serves as a tag, which is layered on the immunoconjugate to 
induce an Ag deposition process. The EC stripping signal of 
the deposited Ag is used to monitor the binding event. The 
nanocomposite-mediated Ag enhancement together with the 
graphene-promoted electron transfer results in high detection 
sensitivity. 
0.05 pg mL
-1
 to 1 ng 
mL
-1 
(0.024 pg mL
-1
) 
(Lin et al, 2014) 
The results obtained from 
clinical serum samples are 
within 12 % (relative error) 
from the commercial 
electrochemiluminescent 
tests.  
A GCE is modified with chitosan and AuNPs to serve as a co-
immobilization matrix for the capture anti-CEA and anti-AFP 
Ab. Two different sensing probes, toluidine blue (TB) for 
CEA and Prussian blue (PB) for AFP, are immobilized onto 
carboxyl graphene nanosheets (CGS), respectively via 
EDC/NHS activation. The detection antibody for each antigen 
is then bioconjugated to its corresponding modified CGS.  
DPV is applied to detect the electrochemical response peak of 
the two probes, before and after the formation of the two 
immunocomplexes.     
0.5-60 ng mL
-1
 for 
both CEA and AFP 
(0.1 ng mL
-1
 for 
CEA and 0.05 ng 
mL
-1
 for AFP) 
 
(Chen et al, 2013)  
The results obtained from 
clinical serum sample are 
in agreement with ELISA 
and there is no cross-talk 
between the two target 
biomarkers. 
A nanocomposite is prepared from rGO/thionine/AuNPs and 
used for coating indium tin oxide sheets. The anti-CEA Ab is 
immobilized on thionine/AuNPs whereas the anti-AFP Ab is 
immobilized on Prussian blue/AuNPs. The decreased response 
current of thionine or Prussian blue is correlated well with the 
corresponding antigen concentration. 
0.01-300 ng mL
-1
 
for both CEA and 
AFP 
(0.650 pg mL
-1
 for 
CEA and 0.885 pg 
(Jia et al, 2014) 
The results obtained from 
clinical serum samples 
agree with ELISA.  
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mL
-1
 for AFP) 
A graphene platform is combined with magnetic beads 
(MaBs) and enzyme-labeled Ab-AuNPs. MaBs coated with 
the cAb is attached to graphene sheets by an external magnetic 
field to preserve graphene conductivity. The HRP-labeled dAb 
is immobilized on AuNPs. Graphene with high surface area 
serves as an electrical transducer. Cyclic voltammetry is used 
to probe the reduction of H2O2 by HRP (Fe
3+
).  
5-60 ng mL
-1
 
(5 ng mL
-1
) 
 
(Jin et al, 2014)  
LOD meets the clinical 
requirement but no real 
samples are tested by this 
approach.   
 
A hybrid architecture of AuNPs-graphene, fabricated by 
reduction of HAuCl4 and GO with ascorbic acid, serves as an 
excellent platform for Ab immobilization. ZnO NPs and 
glucose oxidase (GOx) functionalized graphene labeled 
secondary Ab are designed for this sandwiched ECL assay. 
The in situ generation of H2O2 is achieved by GOx in the 
presence of glucose, a co-reactant of the ECL-luminol 
reaction. The catalysis of ZnONPs to the ECL reaction of 
luminol–H2O2 system is exploited, not conventional HRP  
10 pg mL
-1
 to 80 ng 
mL
-1
 
(3.3 pg mL
-1
) 
 
(Cheng et al, 2012) 
The analytical performance 
is evaluated by adding 
CEA to normal serum 
sample. The recovery 
ranges from 86 to 108 %.  
 
In the diagnosis of cervical cancer, the detection of both CEA 
and squamous cell carcinoma antigen (SCCA) is required.   
Reduced GO-tetraethylene pentamine (rGO-TEPA) with 
amino groups is conjugated to the two capture Ab through 
amidation. Au@mesoporous carbon CMK-3 is synthesized 
and incubated with two detection Abs and two different redox 
molecules: neutral red and thionine. The sandwich structure 
detection scheme is based on the difference of the peak 
current of obtained for the two redox species before and after 
the IMC formation, i.e., absent and present of CEA and 
SCCA. 
0.01-10.0 ng mL
-1
 
(3.8 pg mL
-1
) 
 
(Wu et al, 2014) 
The recovery of 5 ng mL
-1
 
of CEA in serum samples 
ranges from  96-104 %. 
There is no cross-talk 
between CEA and SCCA. 
A GCE is modified by tripetalous cadmium sulfide-graphene 
(CdS-GR) nanocomposites. The L-cystine film on the 
modified electrode is used for aptamer immobilization. The 
response signal is based on the ECL of cadmium sulfide-
graphene (CdS-GR) nanocomposites as the acceptor whereas 
peroxydisulfate acts as the donor. Gold nanoparticles are 
assembled onto the L-cys film modified electrode for aptamer 
immobilization and ECL signal amplification. The decreased 
ECL intensity is correlated directly with increasing CEA 
concentration. Besides its role as an immobilization matrix, L-
cystine also promotes the electron transfer, resulting in 
enhanced the ECL intensity.   
0.01 to 10 ng mL
-1
 
(3.8 pg mL
-1
) 
 
(Shi et al, 2014)  
The recoveries of CEA in 
the human serum samples 
are 85 to 109.5 % with a 
relative standard deviation 
value of less than 3.4%.  
A competitive photoelectrochemical platform is based on 
nanocomposites consisting of CdSe QDs (quantum dots) 
sensitized titanium dioxide decorated rGO. The CdSe/TiO2-
rGO nanocomposite is known to exhibit a high photovoltaic 
conversion efficiency. TiO2–rGO hybrids assemble with 
mercaptoacetic acid wrapped CdSe (MPA–CdSe) QDs 
through electrostatic interaction to form CdSe/TiO2–RGO a 
nanocomposite film. 4-chloro- 1-naphthol 4-CN is oxidized to 
B-4-CHD (benzo-4-chlorohexadienone) by HRP with H2O2 as 
the reductant. Insulating B-4-CHD is then absorbed on RGO 
0.003 to 100 ng mL
-
1
 
(1.38 pg mL
-1
) 
 
(Zeng et al, 2014) 
The CEA results from 
clinical serum samples 
agree with commercial  
turbidimetric immunoassay 
with a relative deviation of 
less than 11.2 %.  
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via π–π conjugation, which led to hinder the AA diffusion to 
the electrode surface for scavenging the holes. The synergic 
effect of HRP and B-4-CHD decreases the background signal, 
providing signal amplification (the light irradiation of 430 nm 
and the applied potential of 0 V. The photocurrent vs the CEA 
concentration plot is linear. 
A chemiluminescence (CL) detection scheme is based on 
aptamer-GO by capillary electrophoresis (CE) using CEA 
aptamer conjugated with HRP and GO. The CE is conducted 
using non-coating quartz capillary (60 cm long with an inner 
diameter of 75 μm). Without CEA, the CL signal obtained 
from the well-known luminol/H2O2 pair) is quenched by the 
HRP-aptamer adsorbed on GO leading to CL resonance 
energy transfer (CRET). In the presence of CEA, HRP-Apt 
forms a stable immunocomplex with this antigen and cannot 
be adsorbed stable on GO. The CL catalyzed by HRP-
Aptamer-CEA complex is detected without CRET, and the 
CEA content is estimated by the CL intensity. 
0.0654 to 6.54 ng 
mL
-1 
(4.8 pg mL
-1
) 
(Zhou et al, 2015) 
Five positive and five 
negative clinical serum 
samples are evaluated. The 
results are in agreement 
with those obtained by a 
LIAISON 
chemiluminescent 
immunoassay system 
(DiaSorinS.p.A, Italy) 
using a standard CEA kit 
(DiaSorinS.p.A, Italy).  
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Highlights 
 Graphene and nanocomposites based immunosensing of carcinoembryonic antigen 
(CEA)  
 General chemistry and bioconjugation strategies for graphene and nanocomposites  
 Clinical significance of CEA as a tumor biomarker and need for CEA detection 
 Immunosensing procedures and trends in technology for the detection of CEA  
 Advances in simultaneous detection of CEA with other pertinent biomarkers  
  
 
 
